https://investors.bms.com/iframes/press-releases/press-release-details/2024/FDA-Advisory-Committee-Votes-in-Favor-of-Bristol-Myers-Squibbs-and-2seventy-bios-Abecma-for-Triple-Class-Exposed-Multiple-Myeloma-in-Earlier-Lines-of-Therapy/default.aspx
https://myelomaresearchnews.com/news/car-t-cell-therapy-farvykti-favored-earlier-multiple-myeloma-treatment/
The ODAC advisory committee has voted in favour for 2 CAR-T therapies in earlier lines of treatment for multiple myeloma. Voting was convincing, bodes well for future CAR-T therapies in earlier lines of treatment.
https://investors.bms.com/iframes/press-releases/press-release-de...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| CHM (ASX) Chart |
Day chart unavailable